Eton Pharmaceuticals, Inc. (ETON)
- Previous Close
3.1400 - Open
3.1100 - Bid 3.0200 x 100
- Ask 3.1400 x 100
- Day's Range
3.0600 - 3.1900 - 52 Week Range
2.4200 - 5.8100 - Volume
68,832 - Avg. Volume
63,685 - Market Cap (intraday)
78.606M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Mar 11, 2024 - Mar 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
www.etonpharma.com30
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ETON
Performance Overview: ETON
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETON
Valuation Measures
Market Cap
78.61M
Enterprise Value
62.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.48
Price/Book (mrq)
5.08
Enterprise Value/Revenue
1.98
Enterprise Value/EBITDA
-215.19
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.96%
Return on Assets (ttm)
-2.62%
Return on Equity (ttm)
-6.56%
Revenue (ttm)
31.64M
Net Income Avi to Common (ttm)
-936k
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
21.39M
Total Debt/Equity (mrq)
35.25%
Levered Free Cash Flow (ttm)
5.6M
Research Analysis: ETON
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell